Table 1.
Demographic and clinical characteristics of ART-experienced patient-years in care, 2000–2016.
| Characteristic | All Patient-Years N=23,169 |
2000–2005 N=7,020 |
2006–2011 N=8,172 |
2012–2016 N=7,977 |
|---|---|---|---|---|
| Sexual risk group, N (%) | ||||
| Heterosexual male | 6,497 (28%) | 2,278 (32%) | 2,298 (28%) | 1,921 (24%) |
| Female | 6,837 (30%) | 2,171 (31%) | 2,400 (29%) | 2,266 (28%) |
| MSM | 9,835 (42%) | 2,571 (37%) | 3,474 (43%) | 3,790 (48%) |
| IDUa, N (%) | 2,849 (12%) | 1,118 (16%) | 1,008 (12%) | 723 (9%) |
| Race/ethnicity, N (%) | ||||
| White | 7,601 (33%) | 2,336 (33%) | 2,667 (33%) | 2,598 (33%) |
| African American | 13,504 (58%) | 4,143 (59%) | 4,707 (58%) | 4,654 (58%) |
| Hispanic or other | 2,064 (9%) | 541 (7%) | 798 (10%) | 725 (9%) |
| Initial ART regimen | ||||
| NRTI-only | 7,761 (34%) | 3,396 (48%) | 2,572 (31%) | 1,793 (22%) |
| Ritonavir-boosted PI | 3,100 (13%) | 411 (6%) | 1,355 (17%) | 1,334 (17%) |
| Unboosted PI | 3,488 (15%) | 1,498 (21%) | 1,190 (15%) | 802 (10%) |
| NNRTI | 6,173 (27%) | 1,237 (18%) | 2,314 (28%) | 2,622 (33%) |
| INSTI | 902 (4%) | 0 (0%) | 111 (1%) | 791 (10%) |
| Otherb | 1,745 (8%) | 478 (7%) | 630 (8%) | 637 (8%) |
| Year of ART start, median (IQR) | 1999 (1996, 2005) | 1997 (1995, 2000) | 2000 (1996, 2005) | 2004 (1998, 2010) |
| Age at ART start, median years (IQR) | 36 (29, 44) | 36 (30, 43) | 36 (30, 44) | 36 (29, 44) |
| CD4 at ART startc, median cells/mm3 (IQR) | 253 (78, 416) | 237 (67, 404) | 240 (68, 403) | 286 (106, 443) |
| Current HIV viremiad, N (%) | 5,694 (25%) | 3,055 (44%) | 1,797 (22%) | 842 (11%) |
| Current CD4 counte, median cells/mm3 (IQR) | 504 (301, 729) | 401 (211, 628) | 496 (304, 714) | 596 (395, 807) |
| Current age, median years (IQR) | 45 (37, 52) | 42 (36, 48) | 46 (38, 52) | 48 (39, 55) |
Abbreviations. ART: antiretroviral therapy. IDU: injection drug use. INSTI: integrase strand transfer inhibitor. IQR: interquartile range. MSM: men who have sex with men. NNRTI: non-nucleoside reverse transcriptase inhibitor. NRTI: nucleoside reverse transcriptase inhibitor. PI: protease inhibitor.
IDU identified as a risk factor for HIV acquisition.
Includes NRTI-sparing regimens (244 person-years), regimens containing more than two classes of agents (724 person-years), regimens containing only an anchor agent (165 person-years), and unknown regimens (612).
Missing for 5,422 (23%) person-years.
Defined as two HIV RNA >500 copies/mL post-ART initiation, or one RNA >500 copies/mL post-ART initiation with no care in the subsequent calendar year, or having a genotype test performed post-ART initiation.
Missing for 581 (3%) person-years.